MedPath

Tagged News

Lila Sciences Achieves Unicorn Status with $235M Funding for AI-Driven Drug Discovery Platform

AIDrug Discovery
  • Lila Sciences secured $235 million in funding, achieving unicorn status with a valuation exceeding $1 billion for its AI-powered drug discovery platform.
  • The Cambridge-based startup is developing the world's first "scientific superintelligence" platform that combines advanced AI models with fully autonomous robotic laboratories.
  • Founded this year with initial $200 million seed funding from Flagship Pioneering, the company aims to revolutionize drug development by automating the entire scientific workflow.
  • Led by CEO Geoffrey von Maltzahn and Chief Scientist George Church from Harvard, Lila's closed-loop system promises to drastically reduce time and costs in drug development.

GE HealthCare Acquires Icometrix to Strengthen Brain MRI Analysis Capabilities for Alzheimer's Drug Monitoring

AI
  • GE HealthCare has acquired brain analysis company Icometrix for an undisclosed sum to expand its Alzheimer's disease diagnostic capabilities.
  • The acquisition centers on Icometrix's FDA-cleared icobrain aria software, which detects and quantifies ARIA side effects from new Alzheimer's drugs like Leqembi and Kisunla.
  • Clinical validation showed the AI-powered software significantly improved radiologists' detection and diagnosis of brain swelling and bleeding complications across 199 test cases.
  • The deal represents GE HealthCare's continued expansion in Alzheimer's diagnostics, following its previous acquisition of MIM Software and integration of amyloid assessment tools.

AMD Partners with Oracle and Absci to Accelerate AI-Driven Drug Discovery Using Advanced GPU Technology

AIDrug Discovery
  • Advanced Micro Devices has formed a strategic collaboration with Oracle Cloud Infrastructure and Absci to advance AI-driven drug discovery using its cutting-edge Instinct MI355X GPUs.
  • The partnership positions AMD to capitalize on the growing intersection of artificial intelligence and pharmaceutical research, potentially enhancing its market position in high-performance computing sectors.
  • AMD's stock has shown strong performance with a 34-35% increase over the last quarter, supported by strategic partnerships and positive market sentiment around AI adoption in healthcare.
  • Despite geopolitical challenges and export restrictions, analysts maintain a consensus price target of $185.77, suggesting potential upside from current trading levels around $155-160.

Tempus AI Receives FDA 510(k) Clearance for Enhanced Cardiac Imaging Platform with T1 and T2 Mapping Capabilities

AIPrecision Medicine
  • Tempus AI received FDA 510(k) clearance for its updated Tempus Pixel, an AI-powered cardiac imaging platform that can now generate T1 and T2 inline maps for enhanced cardiac MR image analysis.
  • The updated device provides precise numerical values for cardiac tissue characteristics, helping clinicians detect conditions such as fibrosis, inflammation, or edema that may otherwise go undetected.
  • Tempus Pixel can generate T1 and T2 inline maps directly from raw MRI data even when the scanner itself does not produce them, calculating values at every pixel across the image.
  • The AI-enabled platform improves efficiency and accuracy in cardiac imaging by providing advanced viewing and automated reporting capabilities for flow visualization, functional analysis, and tissue characterization.

Absci Partners with Oracle and AMD to Accelerate AI-Driven Drug Discovery Platform

AIDrug Discovery
  • Absci, a clinical-stage biotech company, announced a collaboration with Oracle Cloud Infrastructure and AMD to enhance its generative AI Drug Creation Platform for biologics design.
  • The partnership leverages Oracle's AI infrastructure and AMD's next-generation Instinct MI355X GPUs to accelerate molecular dynamics simulations and antibody design workflows.
  • The collaboration enables Absci to reduce inter-GPU latency to 2.5 microseconds and achieve terabytes-per-second throughput for large-scale model training and data streaming.
  • Absci's platform combines AI models with synthetic biology to create novel therapeutics through continuous feedback loops between algorithms and wet lab validation.

Imaging Endpoints Files Patent for AI-Enhanced Imaging Review Charter System to Optimize Oncology Trials

AIOncology
  • Imaging Endpoints has filed a provisional patent application for its revolutionary AI enhanced Imaging Review Charter (IRC) system designed to enhance customized IRCs for oncology clinical trials.
  • The AIRC System addresses long-standing challenges in trial imaging design by providing dynamic customization, criteria optimization, enhanced regulatory compliance, and increased efficiency through AI integration.
  • The company boasts a 95% marketing approval success rate across over 200 regulatory approvals, positioning it as the global leader in oncology imaging CRO services.
  • The system integrates datasets from industry standards, published oncology criteria, and trial information to generate dynamic IRC documents while ensuring alignment with FDA, EMA, and other global regulatory requirements.

Topcon Healthcare Invests in Senseye's AI-Powered Mental Health Diagnostic Platform Using Ocular Biomarkers

AI
  • Topcon Healthcare has made a strategic investment in Senseye, Inc., marking the company's first venture into mental health and neuropsychiatry technology through ocular biomarkers.
  • Senseye's platform uses smartphone-based AI and computer vision to analyze eye metrics in 15 minutes, supporting diagnosis of PTSD, major depressive disorder, and generalized anxiety disorder.
  • The technology enables primary care providers to incorporate objective mental health screening into routine exams, particularly in underserved areas where behavioral health specialists are scarce.
  • The investment supports Topcon's Healthcare from the Eye initiative and opens opportunities for integrating Senseye's technology into Topcon's Harmony platform for comprehensive patient assessment.

insitro and Eli Lilly Partner to Develop AI-Powered ADMET Prediction Models for Small Molecule Drug Discovery

Drug DiscoveryAI
  • insitro and Eli Lilly announced a collaboration to develop advanced machine learning models that can accurately predict key pharmacological properties of small molecules, including their behavior in vivo.
  • The partnership will leverage Lilly's proprietary preclinical data from decades of drug discovery programs to train AI models for predicting ADMET properties, potentially reducing development timelines and costs.
  • The models will be integrated into Lilly TuneLab, a new drug discovery platform designed to accelerate medicine development by providing biotechnology companies access to powerful machine learning tools.
  • Traditional approaches to optimizing pharmacokinetics can take years and cost tens of millions of dollars, making this AI-driven approach a potential game-changer for the industry.

Eli Lilly Launches TuneLab AI Platform to Democratize Drug Discovery for Biotech Companies

AIDrug Discovery
  • Eli Lilly has launched TuneLab, an AI/ML platform providing biotech companies access to drug discovery models trained on over $1 billion worth of proprietary research data.
  • The platform uses federated learning to allow smaller companies to access Lilly's AI capabilities without exposing proprietary data from either party.
  • TuneLab includes comprehensive datasets covering drug disposition, safety, and preclinical data from hundreds of thousands of unique molecules tested by Lilly.
  • The platform aims to address the fundamental challenge faced by early-stage biotechs that lack access to large-scale, high-quality data needed for effective AI model training.

AI Lung Cancer Risk Model Sybil Validated in Predominantly Black Patient Population

AI
  • Researchers at the University of Illinois Hospital & Clinics validated the Sybil AI model's accuracy in predicting lung cancer risk within a predominantly Black patient population, addressing critical racial disparities in screening.
  • The deep learning model achieved an Area Under the Curve of 0.94 for one-year cancer risk prediction, demonstrating remarkable accuracy in a cohort where 62% of participants identified as Non-Hispanic Black.
  • The study analyzed 2,092 baseline low-dose CT screenings over a decade, with 68 patients subsequently diagnosed with lung cancer during follow-up periods extending up to 10.2 years.
  • The Sybil Implementation Consortium plans to initiate prospective clinical trials to integrate the AI tool directly into clinical workflows for real-world lung cancer screening programs.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.